<DOC>
	<DOCNO>NCT00049361</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Thalidomide may stop growth cancer stop blood flow tumor . Combining whole-brain radiation therapy thalidomide temozolomide may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine whole-brain radiation therapy thalidomide temozolomide treat patient newly diagnose brain metastasis .</brief_summary>
	<brief_title>Radiation Therapy Plus Thalidomide Temozolomide Treating Patients With Newly Diagnosed Brain Metastases</brief_title>
	<detailed_description>OBJECTIVES : - Determine overall median survival time patient newly diagnose brain metastasis treat whole-brain radiotherapy combination thalidomide temozolomide . - Determine radiographic response rate , median time tumor progression , median time neurologic response progression patient treat regimen . - Determine cause death patient treat regimen . - Determine toxicity regimen patient . - Assess quality life patient treat regimen . OUTLINE : This multicenter study . Patients undergo radiotherapy daily 5 day week 3 week . Beginning day first radiation treatment , patient receive oral thalidomide daily oral temozolomide daily 21 day . Patients continue receive thalidomide daily 2 year absence disease progression unacceptable toxicity . Quality life assess baseline , 1 3 month complete radiotherapy , every 3 month thereafter . Patients follow 1 3 month every 3 month thereafter . PROJECTED ACCRUAL : A total 62 patient accrue study within 10 month .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm extracranial primary malignancy brain metastasis At least 1 brain metastasis least 1 unresected lesion measurable contrastenhanced MRI No evidence spinal drop metastasis spread noncontiguous meninges No lymphoma , small cell lung cancer , germ cell tumor PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy At least 4 month Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic Bilirubin le 1.5 mg/dL SGPT and/or SGOT great 2 time upper limit normal Renal Creatinine great 1.5 mg/dL BUN great 25 mg/dL Other Able regularly follow No sensory neuropathy great grade 2 No major medical illness would preclude study No neurologic psychiatric impairment would preclude study No active infection Not pregnant nursing Negative pregnancy test Fertile patient must use least 1 highly effective 1 additional effective method contraception 2 month study PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) No concurrent chemotherapy 4 week study Endocrine therapy Not specify Radiotherapy No prior radiotherapy head neck No prior stereotactic radiosurgery Concurrent radiotherapy extracranial sit underlying malignancy allow Surgery Prior craniotomy allow complete within past 1028 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>adult tumor metastatic brain</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>